II. Epidemiology
- 
                          Incidence
                          - Girls: 16.5 per 100,000
- Boys: 7.7 per 100,000
- Harrold (2013) J Rheumatol 40(7): 1218-25 [PubMed]
 
III. Pathophysiology
- Rheumatoid disease in children
IV. Types
- 
                          Pauciarticular (4 or fewer joints involved)- Age at presentation <8 years
- Involves large joints and is typically asymmetric
- Boys may develop Sacroiliitis
- Iridocyclitis may be present
 
- 
                          Polyarticular (>4 joints involved)- Age at presentation 1-6 or 11-16 years
- Involves small joints with symmetric involvement
- Rheumatoid Factor may be positive- Positive Rheumatoid Factor confers similar presentation to Rheumatoid Arthritis in adults
 
 
- Systemic (Still's Disease)- High daily Relapsing Fever >39 degrees persists over 2 weeks (most distinguishes this type from others)
- Polyarticular involvement with >4 joints involved
- Hepatomegaly and Splenomegaly
- Lymphadenopathy
- Pleural Effusion or Pericardial Effusion may be present
- Recurrent evanescent rash- Faint salmon colored rash over trunk, palms and soles
 
 
V. Symptoms
- Pediatric Limp (most common presentation)
- Pain is minimal compared to inflammatory signs- Increasing pain has Negative Predictive Value for RA
 
VI. Signs
- Similar to adult form of Rheumatoid Arthritis- Joint Swelling with warmth (not red and hot)
 
- Differences from Adult Rheumatoid Arthritis- Higher fever
- Rheumatoid Nodules are rare
- Pericarditis and valvulitis are more common
- Lymphadenopathy and Hepatosplenomegaly are common
- Arthritis interferes with bone growth- Example: underdeveloped Mandible
 
- Uveitis most common juvenile RA eye disorder- Occurs in up to 50% of Pauciarticular juvenile RA- Highest risk if ANA positive and recent onset
 
- Asymptomatic in up to 80% of cases
- Delayed diagnosis risks Cataracts, Glaucoma, blind
- Ophthalmology should follow all with juvenile RA
 
- Occurs in up to 50% of Pauciarticular juvenile RA
 
VII. Differential Diagnosis
- Lyme Disease
- Leukemia
- Septic Arthritis
- Osteomyelitis
- Psoriasis
- Inflammatory Bowel Disease
- Streptococcal infection
- Vasculitis
VIII. Labs (often non-diagnostic)
- Precautions- Rheumatoid Factor and Antinuclear Antibody are negative in more than 80% of juvenile RA
 
- 
                          Rheumatoid Factor
                          - Variably positive, often normal
 
- 
                          Antinuclear Antibody
                          - May be associated with Uveitis (see above)
 
- 
                          Erythrocyte Sedimentation Rate (ESR)- High ESR may suggest other diagnoses (e.g. infection)
 
- C-Reactive Protein (CRP)
- 
                          Complete Blood Count
                          - Abnormal in systemic presentation
 
IX. Imaging
- XRay affected joints
X. Diagnosis: Juvenile Idiopathic Arthritis (diagnosis of exclusion)
XI. Management: Maintenance Medications
- NSAIDs
- 
                          Methotrexate 5 to 15 mg/m2/week- NNT 7 for better treatment response than Placebo
- Higher doses that approach the upper range (15 mg/m2) may be more effective
- Tan (2024) Cochrane Database Syst Rev (2):CD003129 [PubMed]
 
- CD-20 Cytolytic Monoclonal Antibody (e.g. Rituxamab)
XII. Management: Exacerbation
- Obtain labs (normal findings do not exclude flare)- Complete Blood Count with differential
- Erythrocyte Sedimentation Rate
- C-Reactive Protein (CRP)
 
- Associated serious conditions- Infection- CD-20 Cytolytic Monoclonal Antibody (e.g. Rituxamab) result in Immunocompromised state
- Labs as above and consider Lactic Acid and Blood Cultures
- Exclude serious infection and treat obvious causes
- Stop Monoclonal Antibody or other Immunosuppressants until infection resolves
 
- Septic Joint- Febrile patient with red, hot joint and increased CRP and ESR
- Joint Aspiration if unclear diagnosis
 
- Macrophage activation syndrome- Cytokine "storm" with similar appearance to Sepsis, with risk of DIC, Acute Renal Failure, Pancytopenia
- Treated with high dose pulse Corticosteroids and supportive care
 
 
- Infection
- Symptomatic flare management- NSAIDs- First-line treatment for mild to moderate Arthritis symptoms if not taken consistently
 
- Corticosteroids- Second-line treatment for moderate to severe Arthritis symptoms, especially if NSAID refractory
- Prednisolone 1-2 mg/kg orally divided twice daily for 3-5 days- Consider initial dose of Methylprednisolone 1-2 mg/kg IV if in Emergency Department
 
 
- Hospitalization indications- Inability to ambulate
- Concurrent serious infection
 
 
- NSAIDs
XIII. Prognosis
- Immunomodulating agents significantly improve longterm outcomes with less chronic Disability
XIV. References
- Claudius, Behar and Chang in Herbert (2016) EM:RAP 16(1): 11-2
- Claudius and Behar in Herbert (2012) EM:RAP-C3 2(8): 2
- Gowdie (2012) Pediatr Clin North Am 59(2):301-27 +PMID:22560572 [PubMed]
- Prince (2010) BMJ 341:c6434 +PMID:21131338 [PubMed]
- Schneider (2002) Rheum Dis Clin North Am 28:503-30 [PubMed]
